Seminars in Oncology Nursing
Volume 23, Supplement 2 , Pages S23-S30, November 2007

Managing Treatment Side Effects in Advanced Breast Cancer

  • Susan Moore

      Affiliations

    • Corresponding Author InformationAddress correspondence to Susan Moore, RN, MSN, ANP, AOCN®, CancerExpertise, 5437 W Warwick Ave, Chicago, IL 60641-3228

Objectives

To compare and contrast the side-effect profiles of antineoplastic therapy options used in the treatment of metastatic breast cancer.

Data Sources

Published research articles, abstracts, and clinical experience.

Conclusion

Novel and existing antineoplastic agents used in the treatment of metastatic breast cancer generally have mild side effects, but can have the potential for serious reactions. Nausea/vomiting, diarrhea, stomatitis/mucositis, and dermatologic and cardiovascular effects are common. Strategies such as dietary changes, over-the-counter remedies, and dose modification can be used to counteract these mild effects.

Implications for Nursing Practice

The oncology nurse should be aware of common adverse events associated with antineoplastic agents, recognize early side-effect signs, and be ready with effective strategies to mitigate side effects when and if they occur.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The development of this article was based on a presentation given by S. Moore at the 2006 Oncology Nursing Society's 7th Annual Institutes of Learning; the author received an honorarium through an educational grant from GlaxoSmithKline.

 Ms Moore has served as a member of the Speaker's Bureau for Roche Laboratories, Genentech Inc., and GlaxoSmithKline.

PII: S0749-2081(07)00092-7

doi:10.1016/j.soncn.2007.10.005

Seminars in Oncology Nursing
Volume 23, Supplement 2 , Pages S23-S30, November 2007